Group 1 - Baichuan Co., Ltd. announced a recent price increase for some of its main products due to market supply and demand factors, but the sustainability of this price fluctuation remains uncertain, making it difficult to predict the impact on the company's performance [1] - Jincheng Co., Ltd. plans to increase its acquisition of CMH Company by an additional 42.50% stake, which will give it a total ownership of 97.5% and ultimate control over CMH [2] - Xinhang New Materials intends to raise no more than 1 billion yuan through a private placement of A-shares, with the funds allocated for projects including high-performance resin production and a composite materials innovation center [3] Group 2 - SMIC reported a sales revenue of $2.489 billion for Q4 2025, a 4.5% increase quarter-on-quarter, with an annual revenue of $9.327 billion, reflecting a 16.2% year-on-year growth [4] - China Railway Construction recently won 10 major projects, each valued over 1.5 billion yuan, totaling 45.142 billion yuan, which represents 4.23% of the company's audited revenue for 2024 [5] - Shenzhen Airport recorded a passenger throughput of 5.8795 million in January 2026, a year-on-year increase of 2.84% [6] Group 3 - China State Construction reported a new contract total of 399.5 billion yuan in January 2026, marking a 1.8% year-on-year increase [7] - Jindi Group's sales amount in January 2026 decreased by 45.78% year-on-year, with a signed area of 78,000 square meters [8] - Changyuan Power achieved a power generation of 3.971 billion kWh in January 2026, a year-on-year increase of 37.81% [9] Group 4 - Senyuan Electric is expected to win a project from the Southern Power Grid valued at 272 million yuan [10] - Chengyi Pharmaceutical's products are set to be selected for the national centralized procurement of expiring varieties [12] - Xinwufeng reported a 10.71% year-on-year decrease in pig sales volume in January 2026 [13] Group 5 - Shengnong Development's sales revenue in January 2026 increased by 40.48% year-on-year, with chicken sales volume rising by 42.79% [14] - Minglida announced the termination of its investment in a key component manufacturing project due to global economic uncertainties [15] - CITIC Securities reported that its subsidiary, Huaxia Fund, achieved a net profit of 2.396 billion yuan in 2025 [16] Group 6 - Pianzaihuang completed the first subject enrollment for its Phase II clinical trial of PZH2107 [17] - Xinzhou Bang reported a 16.56% year-on-year increase in net profit for 2025 [18] - Ankai Bus produced 761 vehicles in January 2026, a year-on-year increase of 35.65% [19] Group 7 - Weilan Bio plans to acquire a 50% stake in Aidimeng Weilan for 47 million yuan [20] - Ningbo Gaofa intends to establish a wholly-owned subsidiary with an investment of no more than 100 million yuan [21] - Shanghai Airport signed a leasing contract worth approximately 585 million yuan with the Shanghai Airport Group [22] Group 8 - Fosun Pharma's subsidiary received acceptance for a drug registration application [23] - Jindai Home's subsidiary invested in acquiring shares in a North American market company [24] - Huatong Co. reported a 1.45% year-on-year decrease in pig sales revenue in January 2026 [25] Group 9 - Yunnan Energy Investment's Nanchong Wind Power Project has been approved with a total installed capacity of 62,500 kW [28] - Youyan Silicon reported a 10.14% year-on-year decrease in net profit for 2025 [29] - Jinpu Titanium announced a temporary shutdown of its Nanjing Titanium White production due to reduced demand [30] Group 10 - Yipin Hong completed the sale of its stake in Arthrosi for a total of $9.5 billion in upfront payments [31] - Liande Co. stated that its gas turbine business currently has limited supply, with minimal impact on overall performance [32] - Tiens Wind Power signed new contracts worth 870 million yuan in the offshore engineering sector [33] Group 11 - Daqin Railway reported a freight volume of 31.28 million tons in January 2026, a year-on-year increase of 5% [34] - ST Mingcheng successfully dismissed all claims from Beijing Fusheng in a recent court ruling [35] - Zhiyang Innovation is planning to acquire control of Lingming Photon and will continue its stock suspension for up to five trading days [36][37] Group 12 - Fulai New Materials accelerated the commercialization of flexible sensors, preparing for mass production of its third-generation electronic skin products [38] - Minhe Co. reported a 36.89% year-on-year decrease in sales of broiler chicks in January 2026 [39] - Ruiang Gene received government subsidies totaling 2 million yuan [40] Group 13 - Huiyu Pharmaceutical's shareholder was forced to reduce holdings by 0.307% due to a court order [41] - Fuyuan Pharmaceutical's subsidiary obtained a drug registration certificate for a new oral solution [42] - Xuantai Pharmaceutical's product is set to be selected for national procurement [43] Group 14 - Chunqiu Electronics completed the cancellation of 9.1369 million repurchased shares [44] - Jinguang Electric won a bid worth approximately 28.8691 million yuan [45] - Hongda Co. plans to invest approximately 71.43 million yuan in a 110kV power transmission project [46] Group 15 - Nanchao Foods reported a 1.99% year-on-year decrease in revenue for January 2026 [47] - Shisheng Intelligent plans to repurchase shares worth between 17.5 million and 35 million yuan [48]

Core Viewpoint - Fuyuan Pharmaceutical (601089.SH) announced that its wholly-owned subsidiary, Anhui Fuyuan, has received a drug registration certificate from the National Medical Products Administration for the production of Bromhexine Hydrochloride Oral Solution [1] Group 1 - The drug approved is Bromhexine Hydrochloride Oral Solution, with a specification of 200ml:160mg [1] - The certificate number for the drug registration is 2026S00394 [1]

证券代码：601089 证券简称：福元医药 公告编号：临 2026-005 北京福元医药股份有限公司 关于盐酸溴己新口服溶液获得药品注册证书的公告 安徽福元于 2024 年 6 月 26 日获得申报受理通知书，并于近日获 得国家药监局批准。根据国家相关政策规定，本次获得《药品注册证 书》视同通过一致性评价。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 近日，北京福元医药股份有限公司（以下简称"公司"）全资子 公司福元药业有限公司（以下简称"安徽福元"）收到了国家药品监 督管理局（以下简称"国家药监局"）颁发的盐酸溴己新口服溶液（规 格：200ml:160mg）（以下简称"该药品"）《药品注册证书》(证书 编号：2026S00394)，批准该药品生产。现将相关情况公告如下： | 药品名称 | 药品通用名称：盐酸溴己新口服溶液 英文名/拉丁名：Bromhexine Hydrochloride Oral | | --- | --- | | | Solution | | 剂型 | 口服溶液剂 | | 注册分类 | 化学药品3类 ...

Core Viewpoint - Fuyuan Pharmaceutical's subsidiary has received approval for a new oral solution, indicating a significant advancement in its product pipeline and potential market opportunities in respiratory treatments [1] Group 1: Product Approval - Fuyuan Pharmaceutical announced that its wholly-owned subsidiary, Fuyuan Pharmaceutical Co., Ltd., has obtained the drug registration certificate for Bromhexine Hydrochloride Oral Solution from the National Medical Products Administration [1] - The approved drug is intended for symptomatic treatment of respiratory diseases related to mucus secretion or clearance disorders in adults, adolescents, and children aged 6 and above [1] Group 2: Financial Investment - As of the announcement date, Fuyuan has invested a total of 1.1143 million yuan (approximately 0.17 million USD) in the research and development of this drug [1]

Group 1: Pharmaceutical Industry - The pharmaceutical index increased by 0.14%, outperforming the CSI 300 index by 1.47% during the week [2][6] - The report highlights the potential of molecular glue technology to target "undruggable" proteins, expanding the scope for innovative drug development [8][9] - Recommended stocks in the innovative drug sector include Heng Rui Medicine, China Biologic Products, and Yuan Dong Biology, among others [11][9] Group 2: Construction and Building Materials - Major engineering projects are identified as a key focus for the "14th Five-Year Plan," with significant investments planned across various provinces [13][14] - The report notes that infrastructure projects will dominate investment, with substantial funding allocated to transportation, municipal, and energy sectors [14] - The issuance of special bonds has increased significantly, with a total of 5,164.55 billion yuan issued as of February 8, 2026, marking a year-on-year increase of 125.35% [15] Group 3: Real Estate - The Shanghai government has initiated the acquisition of second-hand homes for rental housing projects, indicating a strategic move to stabilize the real estate market [19][21] - New home sales in 42 key cities totaled 1.48 million square meters, a slight decrease of 0.1% week-on-week, while second-hand home sales fell by 3.0% [20][19] - The report suggests that the real estate market is entering a phase of structural differentiation, with high-quality housing expected to see increased demand [23] Group 4: Overseas and Education Research - The first round of negotiations between the US and Iran concluded, with market sentiment shifting towards risk assets, particularly in AI and commercial aerospace sectors [26][30] - Bloom Energy reported better-than-expected earnings, with Q4 2025 revenue reaching $777.8 million, a year-on-year increase of 35.9% [26] - The quantum computing sector is gaining attention, with NERSC announcing a call for proposals utilizing neutral atom quantum processors [28]

Core Viewpoint - Fuyuan Pharmaceutical (601089) is progressing with its FY101 injection in Phase I clinical trials, achieving expected results [1] Group 1 - The company is conducting Phase I clinical trials for its FY101 injection as planned, with results meeting expectations [1] - The company plans to submit an IND application for its self-developed new drug FY103 injection by December 2025, which has already received acceptance for clinical trial application at the end of 2025 [1] - The company commits to timely disclosure of project progress in accordance with information disclosure requirements upon obtaining clinical trial approval and officially starting clinical research [1]

证券日报网2月6日讯，福元医药（601089）在接受调研者提问时表示，公司于2025年2月4日完成股份回 购，累计回购股份12000000股，占公司总股本的比例约为2.50%，计划用于股权激励实施。公司将结合 发展战略和人才规划，适时推进股权激励计划，请届时关注公司公告。公司高度重视投资者回报，积极 践行上市公司社会责任，上市至今坚持每年分红，已累计现金分红6.6亿元。 ...

证券日报网2月6日讯 ，福元医药在接受调研者提问时表示，公司创新药的研发立项思路是以市场价值 为导向，聚焦尚未满足的临床需求，进行差异化立项，并切合公司管线及成熟的销售优势。小核酸是继 小分子和抗体后的第三大类药物，福元医药创新药主要聚焦小核酸及小核酸递送系统的研发。公司的 N-ER平台是以福元医药自主研发为技术基础的创新核酸药物发现及递送系统的研发平台。公司已搭建 创新核酸药物设计、合成、修饰、生物学评价、药学研究一体化研发平台。截至目前进展最快的管线在 进行I期临床实验。 （文章来源：证券日报） ...

Investment Rating - The industry investment rating is "Positive" (maintained) [6] Core Insights - The report highlights the significant commercial value of extrahepatic delivery technology for small nucleic acid drugs, which is expanding from liver diseases to multiple disease areas. Domestic companies are rapidly developing multi-target drugs and extrahepatic delivery platforms, which are expected to accelerate the release of potential clinical value [3][8] - The report emphasizes that multinational corporations (MNCs) are intensifying their focus on next-generation delivery platforms, moving from "liver validation" to "multi-organ expansion." This shift is crucial as it addresses unmet clinical needs in various tissues such as fat, muscle, central nervous system, heart, and kidneys [8] - The report indicates that 2026 is a pivotal year for small nucleic acid therapies, with domestic innovative drugs expected to become core assets for transactions. Domestic companies have accumulated rich experience in chemical modifications and liver-targeted delivery technologies, covering high-value areas such as hyperlipidemia, hypertension, hepatitis B, and weight loss [8] Summary by Sections Industry Overview - The report focuses on the pharmaceutical and biotechnology industry in China, specifically on small nucleic acid drugs and their evolving delivery technologies [5][6] Investment Recommendations and Targets - The report lists several investment targets, including: - YK Pharma (688658, Buy) - Hengrui Medicine (600276, Buy) - Xinda Biopharma (01801, Not Rated) - Other companies such as Chengdu XianDao (688222, Not Rated), Reborn Biotech (06938, Not Rated), and others [3]

证券日报网讯 1月29日，福元医药发布公告称，公司2025年度财务报表及内控审计签字注册会计师由廖 屹峰、朱俊杰变更为廖屹峰、简艳会。 （文章来源：证券日报） ...